OW 2025 4 - 7 November 2025

Improvements in Glycemic Parameters and Cardiovascular Risk Factors with Oral Semaglutide 25 mg

Authors :

Domenica Rubino1; Oscar Birkhan2; W. Timothy Garvey3; Naveen Rathor2; Chaithra Shaji4; Sean Wharton5,6,7,8; Ildiko Lingvay9

Affiliations
View Details Hide Details
{{ getPageNum(PDFPage) }}
Download infographic (.pdf)
Download infographic (.pdf)
Keywords
Obesity
Congress oral presentation
GLP-1 RA
Semaglutide (oral)
PHASE 3 (RCT)